PHUNMEDIUM SIGNALFINANCIAL10-K

PHUN shows mixed financial performance with revenue growth offset by deteriorating operating losses and margin compression despite meaningful debt reduction.

The company achieved solid 15.6% revenue growth but operating losses widened substantially while gross profit margins compressed, indicating challenges in controlling costs relative to revenue expansion. The significant reduction in debt load provides some financial flexibility, though the overall profitability trajectory remains concerning for investors.

Comparing 2026-03-27 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

PHUN delivered positive revenue growth of 15.6% to $30.9M but faced operational headwinds with operating losses expanding to $20.5M and gross profit declining to $1.3M, reflecting margin pressure. The company meaningfully improved its balance sheet by reducing total debt nearly in half to $5.2M, though this was partially offset by modest declines in cash reserves and stockholders' equity. The financial picture suggests a company investing in growth (R&D spending up 39.6%) while working through profitability challenges and deleveraging its balance sheet.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-92.2%
$1.7M$135K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Debt
Balance Sheet
-48.2%
$10.1M$5.2M

Debt reduced 48.2% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Income
P&L
-47.7%
-$13.9M-$20.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

R&D Expense
P&L
+39.6%
$2.3M$3.2M

R&D investment increased 39.6% — signals commitment to future product development, though near-term margin impact.

Revenue
P&L
+15.6%
$26.7M$30.9M

Revenue growing 15.6% — solid top-line momentum, watch margins for quality of growth.

Gross Profit
P&L
-11.2%
$1.5M$1.3M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Cash & Equivalents
Balance Sheet
-11%
$113.0M$100.6M

Cash decreased 11% — monitor burn rate and upcoming capital needs.

Net Income
P&L
-10.5%
-$10.3M-$11.4M

Net income declined 10.5% — review whether driven by operations, interest costs, or non-recurring items.

Stockholders Equity
Balance Sheet
-10.1%
$107.2M$96.3M

Equity decreased 10.1% — buybacks or losses reducing book value, monitor solvency ratios.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-31
ADDED
As of March 16, 2026, 20,190,878 shares of common stock, par value $0.0001 per share, were issued and outstanding.
Our sales cycle can be long and unpredictable and our sales efforts require considerable time and expense.
Evolving regulation or industry standards relating to consumer privacy and data protection could impact our business.
Taxing authorities may assert that we should have collected or should collect sales and use, value-added or similar taxes.
Reduced reporting requirements available to us, may cause our common stock to be less attractive to investors.
+7 more — sign up free →
REMOVED
As of March 21, 2025, 20,170,745 shares of common stock, par value $0.0001 per share, were issued and outstanding.
Our sales cycle can be long and unpredictable, particularly with respect to large subscriptions, and our sales efforts require considerable time and expense.
Evolving governmental regulation, legal requirements or industry standards relating to consumer privacy and data protection could impact our business.
Taxing authorities may assert that we should have collected or in the future should collect sales and use, value-added or similar taxes.
Risks Related to Capitalization Matters, Corporate Governance and Market Volatility We may sell additional equity or debt securities or enter into other arrangements to fund our operations, which may result in dilution to our stockholders and impose restrictions or limitations on our business.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →